Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Peter Borchmann, Peter Vandenberghe, Alvaro Urbano-Ispizua, Corinne Haioun, Francois Lemonnier, Laimonas Griskevicius, Sébastien Maury, Silke Holtkamp, Birte Friedrichs, Gregor Zadoyan, Linda Hanssens, Toon Overstijns, Mario Assenmacher, Ulf Bethke, Iris Bürger, Olaf Reer, Ulrich Jaeger, Marie José Kersten

Blood (2022) 140 (Supplement 1): 12784–12785.

https://doi.org/10.1182/blood-2022-164650

Published: 2022

Journal Articles

Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Tatjana Holzer, Stefanie Biedermann, Inga Herfort, Birte Friedrichs, Silke Holtkamp, Linda Hanssens, Mario Assenmacher, Ulf Bethke, Dina Schneider, Stefan Miltenyi, Toon Overstijns, Christoph Schmid, Francis A. Ayuk, Christoph Scheid, Anja Jühling, Udo Holtick, Philipp Gödel, Peter Borchmann, Iris Bürger

Blood (2022) 140 (Supplement 1): 4581–4583.

https://doi.org/10.1182/blood-2022-164597

Published: 2022

Journal Articles

A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts

Andreas Mackensen, Linda Hanssens, Matthias Stelljes, Wolfgang A Bethge, Tobias Feuchtinger, Annette Künkele, Michael Aigner, Alisa Yakushina, Sandra Karitzky, Silke Holtkamp, Mario Assenmacher, Marion Jurk, Georg Rauser, Dina Schneider, Claudia Rossig

Blood (2021) 138 (Supplement 1): 3836.

https://doi.org/10.1182/blood-2021-152452

Published: 2021

Journal Articles

Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-136067

Published: 2020

Journal Articles

Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning

Blood (2018) 132 (Supplement 1): 604.

https://doi.org/10.1182/blood-2018-99-110124

Published: 2018

Journal Articles

First Results of a Prospective Multicenter Phase I/II Clinical Trial in Adult Patients Using Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning

Wolfgang Bethge, MD, Stephan Mielke, MD, Dietger Niederwieser, MD, Roland Meisel, MD, Donald w. Bunjes, MD, Arne Brecht, MD, Jurgen Kuball, MD, Sandra Karitzky, PhD, Silke Holtkamp, Christiane Siewert, PhD, Stefanie Pflitsch, Michael Schumm, DVM, Matthias K. Eyrich, MD, Vladan Vucinic, Markus Wiesneth, MD, Kasper Westinga, Rupert Handgretinger, MD PhD

Blood (2017) 130 (Supplement 1): 213.

https://doi.org/10.1182/blood.V130.Suppl_1.213.213

Published: 2017

Journal Articles

Safety and Efficacy of Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: Results of a Prospective Multicenter Phase I/II Clinical Trial

Peter J. Lang, MD, Paul G. Schlegel, MD, Roland Meisel, MD, Ansgar S. Schulz, MD, Johann Greil, MD, Peter Bader, MD PhD, Sandra Karitzky, PhD, Silke Holtkamp, Christiane Siewert, PhD, Stefanie Pflitsch, Michael Schumm, DVM, Matthias K. Eyrich, MD, Markus Wiesneth, MD, Halvard Bonig, MD MA, Rupert Handgretinger, MD PhD

Blood (2017) 130 (Supplement 1): 214.

https://doi.org/10.1182/blood.V130.Suppl_1.214.214

Published: 2017

Journal Articles

TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: First Results of a Prospective Multicenter Phase I/II Clinical Trial

Peter J. Lang, MD, Paul G. Schlegel, MD, Roland Meisel, MD, Ansgar S. Schulz, MD, Johann Greil, MD, Peter Bader, MD, Sandra Karitzky, PhD, Silke Holtkamp, PhD, Christiane Siewert, PhD, Michael Schumm, VMD, Matthias K. Eyrich, MD, Markus Wiesneth, Halvard Bönig, MD, Rupert Handgretinger, MD

Blood (2016) 128 (22): 389.

https://doi.org/10.1182/blood.V128.22.389.389

Published: 2016

Journal Articles

Decentralized Manufacture of TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Grafts for Children within a Multicenter Phase I/II Clinical Trial

Michael Schumm, VMD, Matthias K. Eyrich, MD, Markus Wiesneth, Halvard Bönig, MD, Peter J. Lang, MD, Paul G. Schlegel, MD, Roland Meisel, MD, Ansgar S. Schulz, MD, Johann Greil, MD, Peter Bader, MD, Murat Aktas, Philipp Dresing, PhD, Sandra Karitzky, PhD, Silke Holtkamp, PhD, Rupert Handgretinger, MD

Blood (2016) 128 (22): 2172.

https://doi.org/10.1182/blood.V128.22.2172.2172

Published: 2016

Journal Articles

Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells

Silke Holtkamp, Sebastian Kreiter, Abderraouf Selmi, Petra Simon, Michael Koslowski, Christoph Huber, Özlem Türeci, Ugur Sahin

Blood (2006) 108 (13): 4009–4017.

https://doi.org/10.1182/blood-2006-04-015024

Published: 2006

NARROW

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts

Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning

First Results of a Prospective Multicenter Phase I/II Clinical Trial in Adult Patients Using Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning

Safety and Efficacy of Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: Results of a Prospective Multicenter Phase I/II Clinical Trial

TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: First Results of a Prospective Multicenter Phase I/II Clinical Trial

Decentralized Manufacture of TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Grafts for Children within a Multicenter Phase I/II Clinical Trial

Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only